{"filings":[{"id":2024359,"accession_number":"0001193125-26-330568","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2026-08-03T20:10:16+00:00","items":["2.02","9.01"],"status":"ready","headline":"ORIC initiates Himalayas-1 Phase 3 trial for rinzimetostat; Q2 cash $387.6M, R&D $36.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Initiated Himalayas-1 global Phase 3 registrational trial for rinzimetostat in mCRPC; ~600 patients, 25 countries, primary endpoint rPFS.","Entered clinical trial collaboration with Bayer to supply darolutamide at no cost for Himalayas-1; ORIC retains full rights to rinzimetostat.","Cash and investments $387.6M as of June 30, 2026; includes $59.9M net proceeds from ATM; runway into 2H 2028.","R&D expenses $36.3M for Q2 2026, up from $30.5M YoY; G&A $9.0M, up from $8.5M.","Anticipated milestones: rinzimetostat program update 2H 2026; enozertinib data at ESMO October 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1969476,"accession_number":"0001193125-26-326309","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2026-07-30T20:49:21+00:00","items":["5.02","9.01"],"status":"ready","headline":"ORIC Pharmaceuticals increases inducement equity plan share reserve by 1.1M shares to 3.35M total","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved Amended and Restated 2022 Inducement Plan, adding 1,100,000 shares of common stock.","Total shares reserved under the plan now 3,350,000 for equity awards to new employees.","Plan allows grants of nonstatutory stock options, RSUs, SARs, performance shares/units.","Adopted without stockholder approval per Nasdaq Listing Rules as inducement grants.","Plan terms are substantially similar to the company's 2020 Equity Incentive Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1194761,"accession_number":"0001193125-26-277511","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2026-06-22T20:05:14+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"ORIC shareholders approve amended equity plan, elect two Class III directors at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amended 2020 Equity Incentive Plan (61.2M for, 27.3M against); annual share increase cut from 5% to 4% of outstanding, evergreen cap removed.","Jacob Chacko, M.D. and Mardi C. Dier elected as Class III directors; Chacko received 89.3M for, Dier 82.0M for.","KPMG ratified as independent auditor for FY2026 with 94.5M votes in favor; advisory say-on-pay passed with 88.5M for.","Advisory vote favored annual frequency of future say-on-pay votes (89.4M for one year); next frequency vote by 2032.","Turnout of 91.4% of outstanding shares; plan amendment saw 27.3M against, reflecting notable shareholder dissent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95522,"accession_number":"0001193125-26-203993","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ORIC Q1 2026: rinzimetostat RP3D for Phase 3; $419.7M cash; enozertinib data due 2H 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Rinzimetostat 400 mg QD + darolutamide data showed landmark rPFS 93%/84%/84% at 3/4/5 months; no Grade 4/5 TRAEs.","Cash and investments $419.7M as of March 31, 2026, including $59.9M from ATM. Expected runway into 2H 2028.","Enrolled Phase 1b enozertinib monotherapy in 1L EGFR exon20 insertion NSCLC; data expected 2H 2026.","R&D expenses $31.4M in Q1 2026 vs $24.6M in Q1 2025, driven by rinzimetostat and enozertinib advancement."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108657,"accession_number":"0001193125-26-134618","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ORIC provides rinzimetostat Phase 1b dose optimization update","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Update covers dose optimization data from Phase 1b trial of rinzimetostat (ORIC-944).","No numerical results or conclusions are disclosed in the 8-K filing itself.","Full data is included in the attached presentation (Exhibit 99.1) dated March 31, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108656,"accession_number":"0001193125-26-064291","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ORIC files new $200M ATM offering; prior program fully utilized","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New prospectus supplement filed Feb 26, 2026 for up to $200M in shares via Jefferies.","Prior $200M program (2024) terminated after raising $139.7M gross from 13.48M shares.","No further sales will be made under the 2024 prospectus supplement.","Legal opinion from Wilson Sonsini filed as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108655,"accession_number":"0001193125-26-063974","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ORIC reports Q4 2025 cash of $392.3M; positive Phase 1b data for rinzimetostat and enozertinib","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $392.3M at Dec 31, 2025; proforma $412.3M after $20M ATM in 2026; runway into 2H 2028.","Raised $264M from healthcare specialist funds in 2025 via private placement ($124.4M) and ATM ($117.6M).","R&D expenses Q4 2025 $25.9M (down 19% YoY); full year 2025 $109.8M (down 4% YoY).","Rinzimetostat Phase 1b: 55% PSA50, 20% PSA90, 76% ctDNA reduction; favorable safety vs competitors.","Enozertinib Phase 1b: 67% ORR in 1L EGFR exon20, 80% ORR in 1L EGFR PACC; 100% intracranial ORR."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125108,"accession_number":"0001193125-25-310472","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ORIC presents enozertinib Phase 1b update; no specific results in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company announced enozertinib (ORIC-114) program update on December 6, 2025.","Update covers data from Phase 1b trial; presentation attached as Exhibit 99.1.","No efficacy or safety figures included in the filing text itself.","Investors must refer to the separate presentation for detailed data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125107,"accession_number":"0001193125-25-280247","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"ORIC updates ORIC-944 dose exploration data in corporate presentation","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["ORIC furnished updated ORIC-944 data slides for investor presentations (Exhibit 99.1).","No specific numerical data or endpoints from the slides were disclosed in the filing.","The presentation is for future use and does not contain financial results or guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125106,"accession_number":"0001193125-25-280196","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ORIC Pharma Q3 2025: $413M cash; ORIC-944 dose exploration complete with positive data","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash and investments of $413M as of Sep 30, 2025; expected to fund operating plan into 2H 2028.","R&D expenses Q3 2025: $28.8M (down $2.4M YoY); G&A expenses: $7.9M (up $0.8M YoY).","ORIC-944 Phase 1b dose exploration completed; PSA50 in 55% (11/20), PSA90 in 20% (4/20), ctDNA clearance in 59% (10/17) mCRPC patients.","Provisional RP2Ds selected for ORIC-944 with darolutamide (400mg/600mg QD) and apalutamide (600mg/800mg/1200mg QD).","Appointed Kevin Brodbeck, PhD as Chief Technical Officer; enozertinib data expected at ESMO Asia Dec 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141809,"accession_number":"0000950170-25-107313","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01","2.05"],"status":"ready","headline":"ORIC Pharma restructures, cuts 20% workforce, and extends cash runway to 2H 2028","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initiated strategic pipeline prioritization, eliminating discovery research and reducing workforce by ~20%; expects ~$1.9M one-time charge in Q3 2025.","Proforma cash and investments of $436.4M as of June 30, 2025, extending cash runway to 2H 2028 (previously 2H 2027).","Q2 2025 R&D expenses $30.5M (up from $28.9M), G&A expenses $8.5M (up from $7.1M); no revenue reported.","ORIC-944 Phase 1b data showed 59% PSA50 and 24% PSA90 responses; enozertinib (formerly ORIC-114) continues enrollment in NSCLC trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159722,"accession_number":"0001193125-25-140725","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"ORIC shareholders elect two Class II directors; KPMG ratified as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["82.02% quorum (58.3M of 71.1M shares) represented at June 11 annual meeting.","Steven L. Hoerter elected with 48.5M for, 410.9K withheld; Angie You elected with 40.0M for, 8.9M withheld.","KPMG LLP ratified as independent auditor for FY2025 with 58.3M for, 44.9K against, 9.9K abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159721,"accession_number":"0001193125-25-129531","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["1.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"ORIC raises $125M; ORIC-944 Phase 1b shows 59% PSA50 response in mCRPC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$125M private placement of 19.2M shares/pre-funded warrants at $6.50/share; led by SR One; close expected May 29, 2025.","Pro forma cash into 2H 2027 funds through first ORIC-944 Phase 3 registrational trial primary endpoint.","ORIC-944 + AR inhibitor achieved 59% PSA50 (10/17), 47% confirmed PSA50, and 24% PSA90 (4/17) in heavily pretreated mCRPC.","Safety mostly Grade 1/2 GI events (diarrhea 53%, one Grade 3); no Grade 4/5 treatment-related AEs.","Phase 1b dose optimization in 2H 2025; first global Phase 3 registrational trial expected to start in 1H 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159720,"accession_number":"0000950170-25-063540","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ORIC Q1 cash $224M; extends runway to 2027; plans Phase 3 for 2 programs in 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $223.8M at March 31, 2025; expected to fund operations into 2027 (vs previous guidance of late 2026).","R&D expenses $24.6M for Q1 2025, up from $22.0M YoY due to pipeline advancement and higher personnel costs.","Registrational plan for ORIC-944 in mCRPC: first Phase 3 trial targeted for 1H 2026; ORIC-114 Phase 3 in 1L NSCLC expected later in 2026.","Entered clinical trial collaboration with Johnson & Johnson for ORIC-114 plus subcutaneous amivantamab in 1L EGFR exon 20 NSCLC."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178106,"accession_number":"0001193125-25-054784","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2025-03-14T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ORIC Pharmaceuticals amends inducement equity plan, adds 1.1M shares to reserve","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Compensation Committee approved Amended and Restated 2022 Inducement Plan, adding 1,100,000 shares to reserve.","Total shares reserved under the plan increased to 2,250,000 shares.","Amendment adopted without stockholder approval under Nasdaq Listing Rules.","Awards are inducement material for new employees and non-employee directors under Nasdaq Rule 5635(c)(4)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178105,"accession_number":"0001193125-25-035203","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ORIC updates registrational plans for lead drugs, extends cash runway into 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ORIC-944 first Phase 3 trial in mCRPC expected 1H 2026; combination dose escalation data in 1H and 2H 2025.","ORIC-114 registrational focus on 1L NSCLC with Phase 3 trials planned 2026; 2L/2L+ registration deprioritized.","Comprehensive NSCLC data update expected 2H 2025 including 1L EGFR exon 20 and atypical cohorts.","Cash, cash equivalents and investments totaled $256M as of Dec 31, 2024; projected runway extended into 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178104,"accession_number":"0000950170-25-022219","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ORIC Pharma Q4/FY2024: $256M cash; R&D spend $114.1M; seven data readouts anticipated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $256M as of Dec 31, 2024; expected to fund operations into late 2026.","R&D expenses Q4 $32.0M (up 31% YoY), FY2024 $114.1M (up 34%).","G&A expenses Q4 $7.6M (up 10%), FY2024 $28.8M (up 13%).","Expects seven data readouts for ORIC-114, ORIC-944 over 18 months; potential registrational trials in 2H25/early 2026.","Entered J&J collaboration for ORIC-114 + amivantamab in NSCLC; completed $125M private placement."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178103,"accession_number":"0001193125-25-005028","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"ORIC Pharmaceuticals presents at JPM 2025; filing lacks specific data","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company presented an updated corporate presentation at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025.","Presentation content not detailed in the filing excerpt; no new financial metrics or guidance provided.","No material changes or forward-looking statements were disclosed in the filing text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194772,"accession_number":"0000950170-24-125386","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ORIC Q3 cash $282.4M, R&D up 39% YoY; ORIC-114 and ORIC-944 on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments of $282.4M as of Sep 30, 2024, expected to fund operations into late 2026.","R&D expenses $31.2M for Q3 2024 vs $22.4M in Q3 2023, increase of $8.8M (39%).","Presented preclinical data supporting best-in-class potential for ORIC-114 in EGFR exon 20 insertion NSCLC; Phase 1b data expected H1 2025.","Entered clinical trial collaboration and supply agreements with Bayer and Johnson & Johnson for ORIC-944 in prostate cancer.","Appointed Keith Lui as SVP of Commercial and Medical Affairs."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211063,"accession_number":"0000950170-24-095419","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ORIC Pharma Q2 cash $308.5M; ORIC-114 expansion and ORIC-944 combo dosing underway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $308.5M as of June 30, 2024; expected to fund operations into late 2026.","R&D expenses $28.9M in Q2 2024 vs $18.8M Q2 2023, up $10.2M on pipeline advancement.","G&A expenses $7.1M in Q2 2024 vs $6.2M Q2 2023, up $0.9M on higher personnel costs.","ORIC-114 Phase 1b dose escalation complete; expansion cohorts in EGFR/HER2 mutant NSCLC dosed; data expected H1 2025.","ORIC-944 combo dosing initiated with NUBEQA and ERLEADA; clinical trial agreements with Bayer and J&J."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229567,"accession_number":"0001193125-24-161593","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"ORIC shareholders re-elect directors; ratify KPMG as auditor for FY2024","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Class I directors Richard Heyman (36.6M for, 11.9M withheld) and Lori Kunkel (48.0M for, 0.5M withheld) re-elected.","KPMG ratification passed: 55.6M for, 6,150 against, 338,222 abstain, no broker non-votes.","Meeting had 55.98M shares represented (83.02% of outstanding); record date April 17, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229566,"accession_number":"0000950170-24-053551","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2024-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ORIC Pharma reports Q1 2024 cash of $331.5M; advances ORIC-114 and ORIC-944 trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $331.5M as of March 31, 2024, expected to fund operations into late 2026.","R&D expenses $22.0M in Q1 2024 vs $19.5M in Q1 2023; G&A $7.0M vs $6.2M.","Initiated three ORIC-114 Phase 1b expansion cohorts in NSCLC with EGFR/HER2 mutations; updated data expected H1 2025.","ORIC-944 initial Phase 1b data supports best-in-class profile; proceeding to combination with AR inhibitor in metastatic prostate cancer.","Strengthened cash with $125M private placement in January 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248094,"accession_number":"0001193125-24-082077","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2024-03-29T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ORIC Pharma boosts inducement equity plan by 650k shares to 1.15M total","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Compensation Committee approved amended 2022 Inducement Plan, adding 650,000 shares.","Total shares reserved under plan now 1,150,000, for equity grants to new employees.","Plan adopted without stockholder approval per Nasdaq inducement award rules.","Awards may only go to individuals not previously employees/directors, as hiring inducement.","Effective March 26, 2024; plan terms substantially similar to 2020 Equity Incentive Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248093,"accession_number":"0000950170-24-029239","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2024-03-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ORIC Pharma Q4 2023: R&D expenses up to $24.5M; cash $235M; pipeline progress on ORIC-944/114","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 R&D expenses $24.5M (up $8.2M YoY); G&A $6.9M; cash and investments $235M at Dec 31, 2023.","Two private placements raised $85M (June 2023) and $125M (Jan 2024); pro forma cash $351.8M at Jan 31, 2024, funding into late 2026.","Initial Phase 1b data for ORIC-114 (EGFR/HER2) and ORIC-944 (PRC2) show best-in-class potential; dose expansion for ORIC-114 in mutated NSCLC expected H1 2024.","ORIC-533 (CD73 inhibitor) Phase 1b dose escalation completed Q1 2024; company plans strategic partnership for combination studies.","ORIC-944 combination study with AR inhibitor to start H1 2024; program update mid-2024. Discovery includes PLK4 inhibitor ORIC-613 advancing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248092,"accession_number":"0001193125-24-011747","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2024-01-22T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"ORIC raises $125M in private placement; extends cash runway into late 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 12.5M shares at $10.00 each; gross proceeds approx. $125M.","Investors include Viking Global, Commodore, Frazier, Venrock, NEA, Nextech.","Premium of ~10% to ORIC's 5-day trailing average price.","Pro forma cash expected to fund operating plan into late 2026.","Private placement expected to close on January 23, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248091,"accession_number":"0001193125-24-004909","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2024-01-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ORIC Pharmaceuticals to present corporate overview at J.P. Morgan Healthcare Conference","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation at 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024.","Corporate presentation furnished as Exhibit 99.1; no material financial or clinical data disclosed in filing.","No new guidance, earnings, or other material events reported in the 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265567,"accession_number":"0001193125-23-292551","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2023-12-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ORIC-533 Phase 1 shows clinical activity in multiple myeloma; company to seek partner, extends cash runway to 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["As of Nov 28, 2023, 23 patients dosed (400-2400 mg QD); 100% triple-class refractory, 91% penta-refractory.","No DLTs, dose reductions, or serious TRAEs; only Grade 1-2 TRAEs observed.","Confirmed minor response in a penta-refractory patient who had progressed on anti-BCMA bispecific.","Dose-dependent immune activation (CD8+ T cells, NK cells) at ≥1200 mg; soluble BCMA reductions at 1600 mg.","Company to complete ORIC-533 dose escalation in Q1 2024 then seek partner; focus on ORIC-114 and ORIC-944."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265566,"accession_number":"0000950170-23-059392","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2023-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ORIC reports Q3 2023 net loss; cash $256.2M; ORIC-114 CNS responses","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and investments $256.2M as of Sept 30, 2023; expected to fund operations into late 2025.","R&D expenses $22.4M in Q3 2023, up from $14.7M in Q3 2022 due to pipeline advancement.","ORIC-114 Phase 1b data at ESMO showed CNS complete response in EGFR exon 20 NSCLC patient; favorable safety.","Initial ORIC-533 data in multiple myeloma to be presented at ASH December 2023.","ORIC-944 initial Phase 1b data in prostate cancer expected Q1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265565,"accession_number":"0001193125-23-260795","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2023-10-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ORIC-114 Phase 1 data shows first confirmed CNS complete response in EGFR exon 20 NSCLC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["81% of EGFR exon 20 NSCLC patients had prior exon 20 targeted agents; 86% had CNS metastases at baseline.","At 75 mg QD (potential RP2D): 67% unconfirmed ORR and 33% confirmed ORR in post-amivantamab patients (n=3).","First confirmed CNS complete response reported by an EGFR exon 20 inhibitor in untreated brain metastases.","HER2 exon 20 patients: partial responses observed, including 100% target lesion regression.","Favorable safety: mostly Grade 1-2 TRAEs; no Grade 3+ rash; 4% discontinuations; MTD not reached."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282762,"accession_number":"0000950170-23-041326","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ORIC Q2 2023 cash $273.7M, $85M private placement; clinical data milestones set","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash and investments $273.7M as of June 30, 2023; expected to fund operating plan into late 2025.","Completed $85M private placement with Nextech, EcoR1, Frazier, Venrock, Boxer investors.","Initial Phase 1b data for ORIC-114 at ESMO Oct 20-24, 2023; ORIC-533 data Q4 2023; ORIC-944 data Q1 2024.","R&D expenses $18.8M in Q2 2023 vs $13.8M in Q2 2022, increase due to program advancement and personnel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302079,"accession_number":"0001193125-23-175501","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2023-06-27T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"ORIC raises $85M in private placement led by Nextech at $7.00/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$85M from sale of ~12.1M shares/pre-funded warrants at $7.00/share (15% premium to 30-day VWAP).","Investors include Nextech, EcoR1 Capital, Frazier Life Sciences, Venrock Healthcare Capital Partners, Boxer Capital.","Proceeds plus existing cash expected to fund operations into late 2025; lock-up until data readout or Dec 31, 2023.","Registration statement for resale to be filed by Jan 31, 2024; closing expected June 27, 2023.","Upcoming data: ORIC-114/533 in H2 2023, ORIC-944 in Q1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302078,"accession_number":"0001193125-23-167893","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2023-06-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"ORIC Pharmaceuticals annual meeting elects directors, ratifies KPMG as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["81.9% of outstanding shares represented at June 14, 2023 annual meeting.","Jacob M. Chacko, M.D. elected with 31,394,488 votes for, 576,707 withheld.","Mardi C. Dier elected with 25,659,351 votes for, 6,311,844 withheld.","KPMG LLP ratified as independent auditor for FY2023: 36,376,853 for, 1,701 against, 553,159 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302077,"accession_number":"0000950170-23-018807","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2023-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ORIC reports Q1 cash $208.9M; three Phase 1b data readouts expected H2 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $208.9M as of March 31, 2023; funds operations into H1 2025.","R&D expenses $19.5M (up $2.7M YoY) driven by clinical and discovery program advancement.","G&A expenses $6.2M, down $0.3M YoY.","Initial Phase 1b data expected H2 2023 for ORIC-533 (myeloma), ORIC-114 (EGFR/HER2), and ORIC-944 (prostate).","Preclinical data for ORIC-944 biomarker strategy and PLK4 program presented at AACR 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321774,"accession_number":"0001193125-23-079104","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2023-03-24T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"ORIC Pharmaceuticals amends bylaws to update proxy rules and conform to Delaware law","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Enhanced disclosure requirements for stockholder nominations and proposals.","Adopted procedural changes to align with SEC universal proxy rules.","Revised meeting provisions per recent DGCL amendments (notice, quorum, adjournment).","Updated exclusive forum provisions and officer/committee authority.","Made ministerial clarifications and conforming revisions throughout."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321773,"accession_number":"0000950170-23-008457","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2023-03-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ORIC Pharma reports Q4 2022 cash of $228.2M; Pfizer invests $25M; Phase 1b data expected H2 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash and investments $228.2M at Dec 31, 2022; runway into first half of 2025.","Pfizer purchased 5.4M shares at $4.65/share for $25M equity investment; collaboration on ORIC-533 + elranatamab combo.","R&D expenses $16.3M in Q4 2022 vs $16.7M in Q4 2021; full-year R&D $61.7M vs $56.9M.","Initial Phase 1b data for ORIC-533, ORIC-114, and ORIC-944 expected in second half of 2023.","Selected a PLK4 inhibitor development candidate; Jeff Settleman (Pfizer) joined Scientific Advisory Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321772,"accession_number":"0001193125-23-004194","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ORIC outlines 2023 milestones: initial Phase 1b data expected H2 2023 for three programs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initial Phase 1b data expected H2 2023 for ORIC-533 (multiple myeloma), ORIC-114 (EGFR/HER2 cancers), ORIC-944 (prostate cancer).","Pfizer invested $25M in ORIC common stock as part of ORIC-533 clinical collaboration.","Cash and investments $228M as of Dec 31, 2022; runway into H1 2025.","Selected PLK4 inhibitor as development candidate for breast cancer (TRIM37-amplified) in Q4 2022.","All three clinical programs dose-escalating steadily without reaching MTD; global site expansion ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339869,"accession_number":"0001193125-22-310169","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2022-12-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ORIC Pharma partners with Pfizer on ORIC-533 Phase 2 combo study; Pfizer invests $25M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pfizer to invest $25M for 5,376,344 shares at $4.65/share in registered direct offering.","ORIC and Pfizer will conduct a Phase 2 study of ORIC-533 combined with elranatamab in multiple myeloma.","Jeff Settleman, Pfizer Oncology CSO, joins ORIC's Scientific Advisory Board.","ORIC retains full ownership of ORIC-533; net proceeds extend cash runway into 1H 2025.","Offering expected to close Dec 23, 2022; no underwriter or placement agent involved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339868,"accession_number":"0000950170-22-022600","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2022-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ORIC reports Q3 2022 cash of $218M; pipeline studies on track for data in 1H 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments of $218.0M as of Sep 30, 2022; expected to fund operations into 2H 2024.","R&D expenses $14.7M (up from $12.9M); G&A $6.0M (up from $5.6M); IPR&D $5.0M milestone for ORIC-114.","Initial Phase 1b data for ORIC-533, ORIC-114, and ORIC-944 expected in 1H 2023.","FDA cleared US IND for ORIC-114; Phase 1b enrolling in South Korea with expansion to US.","Preclinical data on ORIC-533 (CD73 inhibitor) to be presented at ASH Annual Meeting Dec 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357180,"accession_number":"0000950170-22-016870","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2022-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ORIC reports Q2 2022 cash $237.8M; three Phase 1 readouts expected 1H 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $237.8M as of June 30, 2022; funds operations into 2H 2024.","R&D expenses $13.8M for Q2 2022, down from $15.5M in Q2 2021, mainly on lower ORIC-101 costs.","G&A expenses $6.9M for Q2 2022, up from $5.5M in Q2 2021, due to higher personnel costs.","Three ongoing Phase 1 programs (ORIC-533, ORIC-114, ORIC-944) with initial data expected 1H 2023.","Preclinical data on PLK4 inhibitor program presented at AACR in April 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":375766,"accession_number":"0001193125-22-176987","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2022-06-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"ORIC shareholders elect two Class II directors and ratify KPMG as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Steven L. Hoerter and Angie You, Ph.D. elected as Class II directors until 2025 annual meeting.","Hoerter received 30,420,083 for, 21,252 withheld, 3,427,848 broker non-votes.","Angie You received 30,420,703 for, 20,632 withheld, 3,427,848 broker non-votes.","KPMG LLP ratified as independent auditor for FY2022 with 33,863,053 for, 6,025 against, 105 abstain.","Meeting held June 17, 2022 with 85.87% of outstanding shares represented."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":375765,"accession_number":"0000950170-22-008492","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2022-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ORIC Pharma Q1 2022: $256.2M cash runways into 2H2024; three Phase 1b data readouts in 1H2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $256.2M as of March 31, 2022; expected to fund operations into 2H2024.","R&D expenses $16.8M (up $5.1M YoY) driven by advancing ORIC-533, -114, -944; ORIC-101 discontinued.","G&A expenses $6.4M (up $1.6M YoY) due to higher personnel costs.","Three Phase 1b trials (ORIC-533 in multiple myeloma; ORIC-114 in EGFR/HER2; ORIC-944 in prostate) targeting initial data in 1H2023.","PLK4 inhibitor program in lead optimization for TRIM37-amplified breast cancers."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":394096,"accession_number":"0001193125-22-080683","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2022-03-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"ORIC Pharmaceuticals hosts Q4/FY2021 call; corporate presentation furnished as Exhibit 99.1","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Company held conference call on March 21, 2022 to discuss Q4 and full year 2021 financial results and operational update.","Corporate presentation attached as Exhibit 99.1 but specific financial figures are not included in the filing text.","Filing under Item 7.01 Regulation FD; presentation is furnished, not filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":394095,"accession_number":"0001193125-22-080529","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2022-03-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ORIC discontinues ORIC-101 after Phase 1b failures; cash runway extended to 2H 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ORIC-101 discontinued after interim Phase 1b analyses showed insufficient activity; median PFS 3.7 months in prostate, 1.9 months in pancreatic cohorts.","Focus shifts to three single-agent Phase 1b programs: ORIC-533 (multiple myeloma), ORIC-114 (EGFR/HER2), ORIC-944 (prostate); initial data expected 1H 2023.","Cash and investments $280.4M as of Dec 31, 2021; cash runway extended into second half of 2024 following ORIC-101 discontinuation.","Q4 2021 R&D expenses $16.7M (vs $12.1M Q4 2020); G&A $6.1M (vs $4.3M); increases driven by program advancement and public company costs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":394094,"accession_number":"0001193125-22-066051","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2022-03-04T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ORIC Pharmaceuticals adopts 2022 Inducement Equity Incentive Plan reserving 500,000 shares","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Plan adopted March 1, 2022 by Compensation Committee; 500,000 shares of common stock reserved.","Awards limited to new employees as material inducement to hire, per Nasdaq Listing Rule 5635(c)(4).","Terms substantially similar to company's 2020 Equity Incentive Plan.","Adopted without stockholder approval; approved by independent directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":394093,"accession_number":"0001193125-22-005116","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2022-01-10T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"ORIC Pharma reports $280.8M cash; pipeline milestones extend into 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash, cash equivalents and investments of $280.8M as of Dec 31, 2021; funds operations into first half of 2024.","ORIC-101 Phase 1b updates from two combination trials expected in first half of 2022.","Initial Phase 1b data for ORIC-533 (multiple myeloma), ORIC-114 (EGFR/HER2), and ORIC-944 (prostate cancer) expected in first half of 2023.","Two discovery programs advanced into lead optimization; new program/indication to be announced in 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":412679,"accession_number":"0001193125-21-326034","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2021-11-10T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ORIC Pharmaceuticals appoints Angie You to board, Carl Gordon resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Carl Gordon, Ph.D., CFA, resigned as director voluntarily, no disagreement with board.","Angie You, Ph.D., appointed as Class II director, term expires at 2022 annual meeting.","You is CEO of Amunix Pharmaceuticals; previously chief business officer at Sierra Oncology and Aragon.","She receives annual cash retainer of $35,000, committee fees, and stock option for 33,250 shares.","No reportable transactions under Item 404(a) between You and ORIC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":412678,"accession_number":"0000950170-21-003470","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2021-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ORIC Pharmaceuticals reports Q3 2021 cash of $296.5M, ORIC-101 early clinical data, and upcoming pipeline milestones","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and investments of $296.5 million, expected to fund operations into 2024.","Initial Phase 1b data for ORIC-101 combo with enzalutamide showed safe profile and antitumor activity in 6 of 8 key patients.","R&D expenses $12.9M (Q3 2021) vs $8.8M (Q3 2020); G&A expenses $5.6M vs $3.8M.","Anticipated Q4 2021 milestones: initiate Phase 1 trial for ORIC-533 in multiple myeloma and file IND for ORIC-944."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":412677,"accession_number":"0001193125-21-294159","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2021-10-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ORIC presents Phase 1b data on ORIC-101 in prostate cancer and preclinical data on ORIC-114","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ORIC-101 (240 mg) + enzalutamide well tolerated at RP2D; adverse events mostly Grade 1-2, consistent with enzalutamide alone.","No drug-drug interaction; plasma concentrations inhibited GR target; 76% of tumors had moderate-to-high GR expression.","In patients lacking AR resistance markers (n=8), those with moderate/high GR (n=6) had prolonged time on treatment vs low GR (n=2).","ORIC-114 showed superior brain penetration and tumor regressions in HER2+ breast cancer models; 90% CR in EGFR exon20 NSCLC xenograft."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":431362,"accession_number":"0001193125-21-249636","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2021-08-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"SEC ends probe of ORIC CFO Piscitelli with no enforcement action","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CFO Dominic Piscitelli received SEC subpoena in March 2020 re: trading in unrelated companies.","On August 17, 2021, SEC informed Piscitelli investigation concluded without recommending action.","Investigation pertained solely to personal trading of other companies, not ORIC.","Resolution removes potential overhang for CFO and company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":431361,"accession_number":"0001193125-21-247855","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2021-08-16T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"ORIC appoints Steven Hoerter as director; Peter Svennilson resigns from board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Steven L. Hoerter, CEO of Deciphera Pharmaceuticals, appointed as Class II director effective Aug 13, 2021; will serve on Audit Committee.","Peter Svennilson resigned voluntarily as part of planned reduction of public board commitments; had served over six years since TCG's founding investment.","New director Hoerter receives annual retainer of $35,000 plus $7,500 for Audit Committee; granted option for 33,250 shares vesting monthly over 3 years.","Lease amendment expands facility by ~340 sq ft, extends term to May 2028, and landlord contributes $1,514,835 toward improvements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-08-16T23:59:59+00:00|431361"}